Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Panel Discussion (14 mins)
  • CME

Two prostate cancer experts answer audience questions on the use of PARP inhibitors to treat prostate cancer.
Celestia Higano Headshot
Celestia S. Higano, MD, FACP
Program Director
Charles J. Ryan, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 10, 2020 Expiration: August 9, 2021

This program is divided into short segments that you can review from the Activity landing page.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer including the poor prognosis in the absence of targeted treatment
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Interpret test results for predictive markers of PARP inhibitor benefit following evaluation of the available clinical evidence in CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Select PARP inhibitor treatment for appropriate men with prostate cancer
  • Manage adverse events and other barriers to adherence from PARP inhibitors
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Celestia S. Higano, MD, FACP

Professor 
Departments of Medicine and Urology
University of Washington
Seattle, Washington

Celestia S. Higano, MD, FACP, has disclosed that she has received consulting fees from Clovis Oncology, Merck, and Pfizer and funds for research support from Clovis Oncology and Pfizer.

Faculty

Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director,
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Bayer, Janssen, and Sanofi Genzyme; has received funds for research support from Clovis Oncology and the Prostate Cancer Foundation; has received fees for non-CME/CE services from Janssen; and has served in a study leadership position for Clovis Oncology.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors into the treatment of men with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2020, through August 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From ASCO 2020: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from CCO

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 1, 2020 Expired: August 31, 2021

From Clinical Care Options (CCO), an on-demand Webcast on immuno-oncology biomarkers that are key to optimal cancer treatment across multiple tumors

John L. Marshall, MD
Program Director
Jamie E. Chaft, MD Scot Niglio, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 24, 2020 Expired: August 23, 2021

From Clinical Care Options (CCO), watch video of an expert discussion of NTRK fusion testing and TRK inhibitor use in solid cancers

George D. Demetri, MD
Program Director
person default Alexander Drilon, MD Pashtoon Kasi, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 21, 2020 Expired: August 20, 2021

From Clinical Care Options (CCO), video featuring expert presentations on the role of PARP inhibition in the treatment of prostate cancer

Celestia Higano Headshot Celestia S. Higano, MD, FACP
Program Director
Charles J. Ryan, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 10, 2020 Expired: August 9, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?